Pediatric Blood Cancer Program Highlights
Our large program treats many children, giving us a level of expertise and experience that’s unmatched in the area.
Through our relationship with the Children’s Oncology Group (COG), a National Cancer Institute-supported clinical trials group, we have access to the latest treatments, information, and support from all over the world. In addition, we have access to new agent trials through the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium, and we offer CAR T-cell therapy for eligible children with relapsed or refractory acute lymphoblastic leukemia (ALL).
Our own Naomi Winick, M.D., Professor of Pediatrics, has held several leadership positions with COG and is involved in clinical trials for pediatric leukemia.
Patients with pediatric blood cancer treated at UT Southwestern and Children’s Health also have access to:
- A multidisciplinary team that meets weekly to review each current patient’s status
- Molecular diagnostics performed at the time of diagnosis to check for treatable genetic abnormalities in the malignant cells
- Constant assessment of maintenance phase treatments through blood count analysis
- Multiple therapies for relapsed or recurring disease
- A clinical trial involving immunotherapy treatment for acute lymphoblastic leukemia – research that is not available anywhere else in Texas or the surrounding states